433 results on '"Rovira, Ana"'
Search Results
2. Dual mTOR1/2 Inhibitor Sapanisertib (FTH-003/TAK-228) in Combination With Weekly Paclitaxel in Patients With Previously Treated Metastatic Urothelial Carcinoma: A Phase II Open-Label Study
3. NK cell-triggered CCL5/IFNγ-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer
4. Characterization and spatial distribution of the immune cell infiltrate in triple-negative breast cancer: a novel classification based on plasma cells and CD8+ T cells
5. Dual mTOR1/2 inhibitor sapanisertib (TAK-228) in combination with weekly paclitaxel in patients with previously treated metastatic urothelial carcinoma: a phase II open-label study.
6. Targeted metabolomics in formalin-fixed paraffin-embedded tissue specimens: Liquid chromatography-tandem mass spectrometry determination of acidic metabolites in cancer research
7. NK cell-triggered CCL5/IFNγ-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer.
8. Galectins in prostate and bladder cancer: tumorigenic roles and clinical opportunities
9. The impact of mutational clonality in predicting the response to immune checkpoint inhibitors in advanced urothelial cancer
10. Supplementary Figures from CD137 Costimulation Counteracts TGFβ Inhibition of NK-cell Antitumor Function
11. Data from High Numbers of Circulating CD57+ NK Cells Associate with Resistance to HER2-Specific Therapeutic Antibodies in HER2+ Primary Breast Cancer
12. Data from CD137 Costimulation Counteracts TGFβ Inhibition of NK-cell Antitumor Function
13. Supplementary Figures and Tables from High Numbers of Circulating CD57+ NK Cells Associate with Resistance to HER2-Specific Therapeutic Antibodies in HER2+ Primary Breast Cancer
14. Supplementary Tables from CD137 Costimulation Counteracts TGFβ Inhibition of NK-cell Antitumor Function
15. miR-146a-5p Promotes Angiogenesis and Confers Trastuzumab Resistance in HER2+ Breast Cancer
16. Supplementary Data from HER-Family Ligands Promote Acquired Resistance to Trastuzumab in Gastric Cancer
17. Supplementary Figure S5 from Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models
18. Data from mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer
19. Supplementary Table 1 from Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models
20. Data from HER-Family Ligands Promote Acquired Resistance to Trastuzumab in Gastric Cancer
21. Supplementary Table 2 from Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models
22. Supplementary Figures S1-S3 and Tables S1-S4 from c-Jun N-Terminal Kinase Inactivation by Mitogen-Activated Protein Kinase Phosphatase 1 Determines Resistance to Taxanes and Anthracyclines in Breast Cancer
23. Supplementary Figure from mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer
24. Supplementary figure legends from Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models
25. Data from Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models
26. Supplementary Figure S5 from Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation
27. Supplementary Figure S3 from Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer
28. Supplementary Figure 1 from Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer
29. Supplementary Table 1 from Gene Expression Profiling in True Interval Breast Cancer Reveals Overactivation of the mTOR Signaling Pathway
30. Supplementary Figure 3 from Targeting Epithelial-to-Mesenchymal Transition with Met Inhibitors Reverts Chemoresistance in Small Cell Lung Cancer
31. Supplementary Figure 6 from Targeting Epithelial-to-Mesenchymal Transition with Met Inhibitors Reverts Chemoresistance in Small Cell Lung Cancer
32. Supplementary Figure 2 from Targeting Epithelial-to-Mesenchymal Transition with Met Inhibitors Reverts Chemoresistance in Small Cell Lung Cancer
33. Supplementary Methods, Figure Legend, Tables 1 - 6 from Targeting Epithelial-to-Mesenchymal Transition with Met Inhibitors Reverts Chemoresistance in Small Cell Lung Cancer
34. Supplementary Figure 1 from Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer
35. Supplementary Table S3 from Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer
36. Supplementary Figure 2 from Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer
37. Supplementary Figure 2 from Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer
38. Supplementary Figure 1 from Targeting Epithelial-to-Mesenchymal Transition with Met Inhibitors Reverts Chemoresistance in Small Cell Lung Cancer
39. Supplementary Table and Figure Legends from Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer
40. Supplementary Figure 4 from Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer
41. Supplementary Figure 5 from Targeting Epithelial-to-Mesenchymal Transition with Met Inhibitors Reverts Chemoresistance in Small Cell Lung Cancer
42. Supplementary Material and methods from Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation
43. Supplementary Figure 3 from Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer
44. Supplementary Table 1 from Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer
45. Supplementary Figure 7 from Targeting Epithelial-to-Mesenchymal Transition with Met Inhibitors Reverts Chemoresistance in Small Cell Lung Cancer
46. Supplementary Figure 4 from Targeting Epithelial-to-Mesenchymal Transition with Met Inhibitors Reverts Chemoresistance in Small Cell Lung Cancer
47. Supplementary Table 2 from Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer
48. Supplementary Legend from Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation
49. Data from Gene Expression Profiling in True Interval Breast Cancer Reveals Overactivation of the mTOR Signaling Pathway
50. Supplementary Data from NK Cell Infiltrates and HLA Class I Expression in Primary HER2+ Breast Cancer Predict and Uncouple Pathological Response and Disease-free Survival
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.